Walter Robert Bishop

机构：Merck & Co., Inc., Rahway, NJ, USA (United States)

发表论文 128 篇 · 总被引 9040 次 · h-index 43

代表论文

• Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors (2013 · Cancer Discovery · 被引 697)
• Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson–Gilford progeria syndrome (2012 · Proceedings of the National Academy of Sciences · 被引 380)
• Thematic review series: Lipid Posttranslational Modifications. Farnesyl transferase inhibitors (2005 · Journal of Lipid Research · 被引 298)
• Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti–IGF-IR antibody (2005 · Molecular Cancer Therapeutics · 被引 171)
• The Farnesyl Transferase Inhibitor (FTI) SCH66336 (lonafarnib) Inhibits Rheb Farnesylation and mTOR Signaling (2005 · Journal of Biological Chemistry · 被引 165)
• Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors (2018 · JCI Insight · 被引 153)